Pancreatic Cancer Meets Human Microbiota: Close Encounters of the Third Kind.

ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal types of cancer with a dismal prognosis. The five-year survival rate has not changed significantly in over 40 years. Current first-line treatments only offer a modest increase in overall survival in unselected populations, and there is an urgent need to personalize treatment in this aggressive disease and develop new therapeutic strategies. Evolving evidence suggests that the human microbiome impacts cancerogenesis and cancer resistance to therapy. The mechanism of action and interaction of microbiome and PDAC is still under investigation. Direct and indirect effects have been proposed, and the use of several microbiome signatures as predictive and prognostic biomarkers for pancreatic cancer are opening new therapeutic

SUBMITTER: Arsenijevic T 

PROVIDER: S-EPMC7998494 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature